Nicotinamide Cooperates with Retinoic Acid and 1,25-Dihydroxyvitamin D3 to Regulate Cell Differentiation and Cell Cycle Arrest of Human Myeloblastic Leukemia CellsShen M. · Yen A.
Department of Biomedical Sciences, Cornell University, Ithaca, N.Y., USA Corresponding Author
Nicotinamide, the amide derivative of vitamin B3, cooperates with retinoic acid (RA), a form of vitamin A, and 1,25-dihydroxyvitamin D3 (D3), to regulate cell differentiation and proliferation of human myeloblastic leukemia cells. In human myeloblastic leukemia cells, RA or D3 are known to cause MAPK signaling leading to myeloid or monocytic differentiation and G0 cell cycle arrest. In this process, RA or D3 induces the early expression of CD38, a receptor that causes ERK signaling and propels further differentiation. Our study demonstrates that nicotinamide in combination with RA or D3 affected induced expression levels of CD38, CD11b and CD14, suggesting a cooperative function of nicotinamide and RA or D3. Nicotinamide transiently retarded the initial RA- or D3-induced expression of CD38, which subsequently reached the same nearly 100% expression. Nicotinamide induced ERK activation and further enhanced the RA-induced ERK activation, but the D3-induced ERK activation was diminished by nicotinamide, although levels still exceeded those induced by RA, suggesting lineage-specific nicotinamide responses. Nicotinamide enhanced both RA- and D3-induced CD11b expression, inducible oxidative metabolism, and G0 cell cycle arrest, accelerating their induced occurrence in all instances. Consistent with this, the RA- or D3-induced downregulation of PARP was enhanced by nicotinamide. Nicotinamide thus regulated RA- or D3-induced differentiation and G0 arrest, causing a transient delay in certain early aspects of the progression to terminal differentiation but ultimately accelerating the occurrence of terminally, functionally differentiated G0 cells.
© 2009 S. Karger AG, Basel
Nicotinamide, the amide derivative of vitamin B3, is a precursor used by cells for the synthesis of nicotinamide adenine dinucleotide, which is known to play a major role as a co-enzyme in numerous oxidation-reduction reactions . Studies by Ogata et al.  suggest that nicotinamide acts as an inducer of apoptosis in HL-60 cells. More interestingly, some studies show that nicotinamide represents a pharmacological agent, and has been reported to exert inhibitory effects on poly(ADP-ribose) polymerase (PARP) . PARPs have been involved in DNA repair and replication [4, 5], cell viability, apoptosis and regulation of numerous cellular functions [6, 7]. Szabo  indicated that PARP inhibition not only prevents the development of diabetic endothelial dysfunction, but also restores normal vascular function in established diabetes. Thus, as a PARP inhibitor, nicotinamide may be useful in the therapy of diseases, where PARP is thought to play a role.
Nicotinamide has been used in a broad spectrum of diseases, such as preventing streptozotocin-induced diabetes in rats  or exerting protective effects on acute lung injury caused by ischemia-reperfusion . Therefore, new functions of nicotinamide, such as use as anticancer tools, are of interest. It was shown that several niacin-related compounds including nicotinamide had an effect on the differentiation of leukemia cells [11, 12]. Studies by Munshi et al.  showed that nicotinamide inhibited retinoic acid (RA)-induced CD38 expression and differentiation. Niacin-related compounds such as isonicotinamide or vitamin B3 had histone deacetylase(HDAC) inhibitory activity, like phenyl butyrate, and affected leukemic cell differentiation . Merzvinskyte et al.  showed that treating HL-60 cells with both sodium phenyl butyrate plus vitamin B3, prior to RA treatment caused enhanced CD11b expression, inducible oxidative metabolism, and cell cycle arrest, suggesting that niacin-related compounds may regulate cell differentiation. Nicotinamide may thus affect a variety of processes that regulate proliferation and differentiation [11, 14], including cellular response to RA or 1,25-dihydroxyvitamin D3 (D3), two well-known inducers of differentiation.
RA or D3 are known to induce HL-60 myeloblastic leukemia cells to undergo G0 cell cycle arrest and myeloid or monocytic differentiation . Our previous studies have indicated that in HL-60 cells RA and D3 cause ERK phosphorylation and activation of MAPK signaling leading to myeloid or monocytic differentiation and G0 cell cycle arrest . In this process RA or D3 induces the early expression of CD38, which is associated with lipid rafts upon receptor stimulation, and signals through MAPK to promote cell differentiation [17, 18]. These considerations motivate the anticipation that nicotinamide may cooperate with RA or D3 to regulate cell differentiation and proliferation.
In this study, we investigated whether nicotinamide affects processes involved in control of proliferation and differentiation that regulate RA- or D3-induced differentiation and cell cycle arrest. This would contribute to understanding the mechanism of differentiation and cell arrest for inducers used in the treatment of leukemia . This study also showed interesting evidence that nicotinamide worked together with RA or D3 to regulate functional cell differentiation and cell cycle arrest. Nicotinamide has already been used in the clinic to treat various diseases [20, 21]; the finding thus has interesting clinical relevance. Nicotinamide also induced ERK activation and further enhanced the ERK activation induced by RA, but diminished the D3-induced enhanced ERK activation, suggesting that nicotinamide differentially affects HL-60 cell myeloid or monocytic differentiation. Our study provides a comprehensive scientific evaluation of the differential roles of nicotinamide in RA- or D3-induced differentiation and cell cycle arrest. The data suggest the potential advantage of combined RA/nicotinamide therapy.
Human myeloblastic leukemia cells (HL-60) were grown in a humidified atmosphere of 5% CO2 at 37°C and maintained in RPMI 1640 supplemented with 5% fetal bovine serum (Invitrogen, Carlsbad, Calif., USA). The cells were cultured in constant exponential growth as previously described . The experimental cultures were initiated at a cell density of 0.2 × 106 cells/ml. Viability was monitored by 0.2% trypan blue (Invitrogen) exclusion and routinely exceeded 95% prior to drug administration.
RA (Sigma, St. Louis, Mo., USA) and D3 (Cayman, Mich., USA) were dissolved in 100% ethanol with a stock concentration of 5 and 1 mM, and used at a final concentration of 1 and 0.5 μM, respectively, as previously described . Nicotinamide (Sigma, St. Louis, Mo., USA) dissolved in water with a stock concentration of 1 M was used at a final concentration of 10 mM and added at the same time as RA and D3 treatment.
HL-60 cells (0.5 × 106) were harvested by centrifugation at 700 g for 5 min. Cells were resuspended in 100 μl PBS containing 5 μl of APC-conjugated CD11b, PE-conjugated CD38 (BD Biosciences, San Jose, Calif., USA), and FITC-conjugated CD14 (Biolegend, San Diego, Calif., USA). Following incubation for 1 h at 37°C, cells were analyzed by flow cytometry (LSRII flow cytometer, BD Biosciences). For CD11b expression, cells were analyzed by 633-nm red laser excitation and collecting emitted fluorescence through a 735 long-pass dichroic and a 660/20 band-pass filter. For CD38 and CD14, cells were analyzed by flow cytometry using 488-nm blue laser excitation, and emitted florescence was collected through a dichroic 550 long-pass and 576/26 band-pass, and a dichroic 505 long-pass and 530/30 band-pass filter, respectively. The threshold to determine percent increase of expression was set to exclude 95% of control cells.
Cells (0.5 × 106) were fixed by resuspension in 100 μl PBS with 2% paraformaldehyde (Alfa Aesar, Ward Hill, Mass., USA) for 10 min incubation at room temperature and then permeabilized by addition of 900 μl –20°C methanol for 20 min at –20°C. Following incubation and two washes, cells were stained with Alexa 647-conjugated phospho-p44/42 MAPK (Cell Signaling, Beverly, Mass., USA) for 1 h and analyzed by flow cytometry (BD LSRII) using 633-nm red laser excitation with emitted florescence reflected from a dichroic 735 long-pass through a 660/20 band-pass. The gate to determine percent increase in expression was set to exclude 95% of HL-60 control cells, which represents basal levels of pERK. Cell populations exceeding basal ERK upon RA treatments were detected by their positive shift above the basal levels from control cells. The percentage of positive cells is reported and thus is a measure of the shift in the pERK per cell flow-cytometric histogram.
Cells (0.5 × 106) were fixed and permeabilized as described above. After washing twice with 1 ml PBS, cells were stained with anti-PARP monoclonal antibody (Trevigen, Gaithersburg, Md., USA) for 1 h at room temperature. Following incubation and washing, cells were stained with an Alexa 350-conjugated goat anti-mouse secondary antibody (Invitrogen) for 1 h and analyzed by flow cytometry using 325 nm excitation with emitted fluorescence reflected from a 505 long-pass dichroic through 440/40 band-pass filter. Results given as mean fluorescence intensity were determined by quantifying the fluorescence intensity of the gated entire cell population.
0.5 × 106 cells were harvested by centrifugation and resuspended in 200 μl 37°C PBS containing 10 μM 5 (and 6)-chloromethyl-2′,7′-dichlorodihydro-fluorescein diacetate acetyl ester (H2-DCF, Molecular Probes, Eugene, Oreg., USA) and 0.4 μg/ml 12-O-tetradecanoylphorbol-13-acetate (TPA, Sigma, St. Louis, Mo., USA) with incubation for 20 min in a humidified atmosphere of 5% CO2 at 37°C. Flow-cytometric analysis was done (BD LSRII flow cytometer) using 488 nm excitation laser and emission collected through a 505-nm long-pass dichroic and 530/30 nm band-pass filter. The shift in fluorescence intensity in response to TPA was used to determine the percent cells with the capability to generate inducible superoxide. Gates to determine percent positive cells were set to exclude 95% of control cells. Control cells with or without TPA and RA-treated cells without TPA typically showed indistinguishable DCF fluorescence histograms.
0.5 × 106 cells were collected by centrifugation and resuspended in cold (4°C) 200 μl hypotonic staining solution containing 50 μg/ml propidium iodine, 1 μl/ml Triton X and 1 mg/ml sodium citrate. Cells were incubated at room temperature for 1 h and analyzed by flow cytometry (BD LSRII) using 488-nm excitation and collection through a 550 long-pass dichroic and a 576/26 band-pass filter.
Three independent repeats were conducted in all experiments. Error bars represent three repeats. StatView statistical package (SAS Institute, Version 5.0.1) was used to analyze the data via ANOVA, Fisher’s PLSD.
In this study, the ability of nicotinamide to regulate HL-60 cell differentiation in response to different treatments (RA, D3, or nicotinamide or their combinations) was measured using a cell surface marker and a functional differentiation marker. First, a cell surface differentiation marker, CD11b, was used to measure cell differentiation by immunofluorescence using APC-conjugated CD11b antibody. CD11b, a cell surface antigen, functions as a receptor for complement (C3bi), fibrinogen, or clotting factor X. RA or D3 induces CD11b expression in HL-60 cells [23, 24]. To determine the effects of nicotinamide (Nam) on CD11b expression, we compared CD11b expression in HL-60 untreated cells (control), and cells treated with RA, Nam plus RA, D3, Nam plus D3 and Nam alone for 24, 48 and 72 h using flow cytometry. Compared to cells with just RA or D3 treatment, cells treated with Nam plus RA or D3 showed enhanced expression of CD11b (fig. 1a, b). For example, at 24 h, the cells treated with Nam plus RA or Nam plus D3 showed a 1.6- or 2.0-fold increase in CD11b expression compared to the cells treated with RA or D3 alone. Figure 1a shows that nicotinamide increased the rate of induced CD11b expression from 24 to 72 h, indicating an acceleration of the induced differentiation. Figure 1b shows CD11b expression histograms after 24 h RA treatments. In cells treated with Nam alone, the expression of CD11b was the same as in untreated control cells, indicating that nicotinamide alone does not affect the expression of the CD11b cell surface differentiation marker. But when combined with RA or D3, nicotinamide enhanced the rate of induced CD11b expression.
|Fig. 1. Nicotinamide (Nam) enhanced RA- or D3-induced CD11b expression. a CD11b expression was enhanced by RA, D3 and Nam as indicated by flow cytometry. Untreated control (C) cells and cells treated with RA, Nam plus RA (N/RA), D3, Nam plus D3 (N/D3), and Nam alone (N) for the indicated times were stained with APC-conjugated CD11b, and the percent of cells expressing CD11b was analyzed by flow cytometry. b Representative CD11b expression histograms of untreated and treated (RA, N/RA, D3, N/D3, and N) HL-60 cells after 24-hour treatments. a CD11b expression in cells treated with RA, N/RA, D3 and N/D3 was significantly different from that in untreated cells at the corresponding time; b p ≤ 0.05, N/RA or N/D3 treatment was significantly different from treatments with RA or D3 alone.|
HL-60 cells undergo G0 cell cycle arrest and myeloid differentiation in response to RA or monocytic differentiation in response to D3. To confirm the regulation of cell differentiation by nicotinamide and RA or D3, a functional differentiation marker, inducible oxidative metabolism was used. Inducible oxidative metabolism is a hallmark of terminally differentiated myeloid cells. The chemically reduced and acetylated form of 2′,7′-dichlorohydrofluorescein diacetate (H2DCFDA), known as chlorofluorescein diacetate, is a cell-permeant fluorescent indicator for reactive oxygen species. H2DCFDA is nonfluorescent until the acetate groups are removed by intracellular esterases and oxidation occurs within the cell. The oxidation of the nonfluorescent H2DCFDA to the highly fluorescent DCF was used to detect the generation of reactive oxygen species. Inducible oxidative metabolism can be used as a functional marker of mature myeloid and monocytic cells. HL-60 cells treated with Nam plus RA or D3 showed slower differentiation at early time points, but underwent faster differentiation at later time points compared to treatments with RA or D3 alone (fig. 2). At 48 h, HL-60 cells treated with Nam plus RA or D3 showed reduced RA- or D3-induced differentiation compared to cells treated with RA or D3 alone (62 or 57% in RA or D3, 39 or 13% in Nam plus RA or Nam plus D3). Cells treated with Nam plus D3 resulted in a significant decrease in the percentage of cells capable of inducible oxidative metabolism compared to cells treated with Nam plus RA, suggesting that Nam may function differently in myeloid or monocytic differentiation. In contrast by 72 h of treatment, Nam plus RA or D3 increased the percentage of cells capable of inducible oxidative metabolism compared to cells treated with RA or D3 alone. It was striking that Nam first retarded and then accelerated functional differentiation. Nam thus apparently had differential effects on cells that were earlier or later in the RA or D3-induced progression to terminal myeloid or monocytic differentiation. The cells treated with Nam alone showed no differentiation, which was consistent with results from CD11b expression, suggesting that nicotinamide alone did not affect cell differentiation in HL-60 cells.
|Fig. 2. Nicotinamide (Nam) affects RA- or D3-induced functional differentiation. Cells treated with Nam plus RA (N/RA) or D3 (N/D3) underwent slower functional differentiation at the early time point (48 h), but showed faster differentiation at the later time point (72 h) compared to treatments with RA or D3 alone by using a functional differentiation marker, DCF. The percentage of positive cells for 48 and 72 h after treatment for control (C), RA, N/RA, D3, N/D3, and Nam (N) is shown. Cells were incubated in PBS containing DCF and TPA and analyzed by flow cytometry. Gates to determine percent positive cells were set to exclude 95% of control cells. a DCF expression levels in cells treated with RA, N/RA, D3 and N/D3 were significantly different from that in untreated cells; b p ≤ 0.05, N/RA or N/D3 treatment was significantly different from treatments with RA or D3 alone.|
RA- or D3-treated terminally differentiated cells are growth arrested [19, 25]. To determine the effects of nicotinamide on RA- or D3-induced G1/G0 cell cycle arrest, the percentage of untreated control, RA, Nam plus RA, D3, Nam plus D3, and Nam cells, in G1/G0 was measured using flow cytometry (fig. 3a, b). G1/G0 arrest would be revealed by an enrichment of cells with G1 DNA. Previous studies [16, 26] indicated that RA or D3 induced G0 arrest, and our study here shows that Nam enhanced RA- or D3-induced G0 arrest. However, cells treated with Nam alone did not undergo cell cycle arrest. The effects of Nam on growth arrest were consistent with the effects on the differentiation after 72 h treatments, indicating the role of nicotinamide in promoting RA- or D3-induced differentiation and cell cycle arrest. To confirm that the changes in differentiation and promotion of cell cycle arrest caused by nicotinamide reflected decreased cell growth, the growth of RA-, Nam plus RA-, D3-, and Nam plus D3-treated cells was measured. Figure 3c indicated that there was curtailed cell growth associated with G0 enrichment in Nam-treated cells.
|Fig. 3. Nicotinamide (Nam) accelerated G0 arrest. a Representative histograms of percentage of cells with G1/G0 DNA after 48-hour treatments with RA, Nam plus RA (N/RA), D3, Nam plus D3 (N/D3), and Nam (N), and untreated (control, C). b Nicotinamide enhanced G0 arrest after 48- and 72-hour treatment. The percentage of G1 DNA cells at 48 and 72 h after treatment for control (C), RA, N/RA, D3, N/D3, and N is shown. Cells stained with hypotonic staining solution were incubated for 1 h and analyzed by flow cytometry. a Percentage of G1 in cells treated with RA, N/RA, D3 and N/D3 was significantly different from that in untreated cells; b p ≤ 0.05, N/RA or N/D3 treatment was significantly different from treatments with RA or D3 alone. c HL-60 cells upon nicotinamide treatments grew slowly compared to cells treated with RA or D3 alone or untreated cells.|
ERK activation is known to propel cell differentiation and cell cycle arrest . In particular ERK drives p21waf1/cip1 expression to propel growth arrest as well as differentiation . To investigate if regulation of RA- or D3-induced myeloid or monocytic differentiation and cell cycle arrest by nicotinamide was related to ERK activation, we compared ERK activation in HL-60 cells treated with RA, Nam plus RA, D3, Nam plus D3, and Nam. Dual phosphorylated ERK [T(203) EY(205)] was measured by flow cytometry. All treated cells show increases in activated ERK per cell above basal levels of control cells in all treated cells, suggesting that RA, D3, and Nam all caused ERK activation (fig. 4). Cells treated with Nam plus RA showed increased activated ERK per cell compared to cells treated with RA or Nam alone, suggesting that Nam and RA function additively for activation of ERK expression. Treating cells with Nam alone increased ERK activation, but did not produce cell differentiation. This suggested that enhanced ERK activation facilitates RA-induced differentiation, but is not the only driver needed to promote cell differentiation. In contrast, ERK activation was not as elevated in cells treated with Nam plus D3 compared to cells treated with D3 alone. These differential effects on ERK activation in cells treated with Nam plus RA and Nam plus D3 coincide with the differential effects of nicotinamide on HL-60 cell myeloid or monocytic differentiation.
|Fig. 4. Nicotinamide (Nam) affected ERK2 activation. Percentage of cells with pERK exceeding basal levels of untreated controls in RA, Nam plus RA (N/RA), D3, Nam plus D3 (N/D3), and Nam (N) treatments after 24 h is shown. HL-60 cells treated with N/RA caused enhanced ERK activation; however, cells treated with N/D3 showed decreased ERK expression after 24 treatments. Cells fixed and permeabilized were stained with Alexa 647-conjugated phospho-p44/42 MARK, and mean fluorescence intensity was determined by quantifying the fluorescence intensity of the entire cell population. a Percentage of pERK in cells treated with RA, N/RA, D3 and N/D3 was significantly different from that in untreated cells; b p ≤ 0.05, N/RA or N/D3 treatment was significantly different from treatments with RA or D3 alone.|
The above differentiation data showed that cells treated with Nam plus RA or D3 underwent slower differentiation at early time points (48 h), but showed faster differentiation at later time points (72 h) compared to treatments of RA or D3 alone. These different effects of nicotinamide in combination with RA or D3 may reflect differential effects of various nicotinamide targets as cells progress toward RA- or D3-induced terminal differentiation. Since nicotinamide enhanced the expression of the late marker CD11b, its effect on earlier putative regulatory progresses became of interest. CD38 is amongst the earliest membrane receptors upregulated by RA and D3, and it signals through MAPK to help propel RA- or D3-induced differentiation and cell cycle arrest in G1/G0, making it of functional significance to induced differentiation. Comparing cells treated with RA or D3 alone and cells treated with Nam plus RA or Nam plus D3, Nam retarded the RA- or D3-induced expression of CD38 (fig. 5a, b). The differences were evident at 6 and 12 h of treatment. After 6 h treatments, CD38 expression levels in the cells treated with Nam plus RA or Nam plus D3 showed a 2.4- or 3.0-fold decrease compared to the cells treated with RA or D3 alone, and at 12 h CD38 expression levels were decreased 1.4- to 1.5-fold in the cells treated with Nam plus RA or D3. But most cells (except control and Nam-treated cells) had attained similar maximal expression levels by 24 h (approximately a 1.1-fold decrease in Nam treatment groups). This suggested that cells treated with Nam plus RA or Nam plus D3 expressed CD38 more slowly. Since CD38 signals through MAPK to promote cell differentiation , reduction of CD38 expression by Nam slows early processes providing a rationale for slower functional cell differentiation at the 48-hour time point. In cells treated with Nam alone, there was no CD38 expression, suggesting that Nam alone does not affect CD38 expression.
|Fig. 5. Nicotinamide (Nam) inhibited CD38 and CD14 expressions. a Percent of cells expressing CD38 after RA, Nam plus RA (N/RA), D3, Nam plus D3 (N/D3), and Nam (N) treatments for the indicated times compared to untreated control cells. RA and D3 enhanced CD38 expression; however, Nam inhibited CD38 expression. b Representative CD38 expression histograms of untreated (C) and treated (RA, N/RA, D3, N/D3, N) HL-60 cells. Cells were incubated in PBS containing PE-conjugated CD38, and CD38 expression levels were analyzed by flow cytometry. c Nam inhibited RA-induced CD14 expression (72 h) by flow cytometry. a Expression levels of CD38 and CD14 in cells treated with RA, N/RA, D3, N/D3, and N were significantly different from that in untreated cells; b p ≤ 0.05, N/RA or N/D3 treatment was significantly different from treatments with RA or D3 alone.|
To corroborate these CD38 results, the effects of Nam on the CD14 cell differentiation marker were determined. CD14 is a membrane-associated glycosylphosphatidylinositol-linked protein expressed at the surface of cells, and takes its name from its inclusion in the cluster group of cell surface marker proteins. CD14 can bind to lipopolysaccharide. When lipopolysaccharide binds to CD14, the cells become activated and release cytokines such as tumor necrosis factor and upregulate cell surface molecules, including adhesion molecules [28, 29]. In cells treated with Nam plus RA or D3 compared to RA or D3 alone, Nam diminished induced CD14 expression (fig. 5c). The CD14 expression levels in the cells treated with Nam alone were not significantly different compared to control cells, suggesting that Nam alone does not affect CD14 expression. The effects of Nam on CD14 expression were consistent with effects on CD38 expression.
PARP is thought to function in many important cellular processes, such as cell proliferation, gene transcription, cell differentiation, apoptosis, and DNA repair [30, 31]. In particular PARP-1 interacts with RAR and regulates RA signaling , suggesting its potential involvement here. To test the effects of nicotinamide on PARP expression in HL-60 cells, we measured the expression of PARP by flow cytometry in cells with RA, D3 and Nam treatments. Figure 6 shows that RA or D3 decreased PARP expression and Nam enhanced the decrease, consistent with the effects it had enhancing certain aspects of induced differentiation and arrest.
|Fig. 6. Nicotinamide (Nam) inhibited PARP expression. HL-60 cells treated with Nam plus RA (N/RA) or D3 (N/D3) caused a decreased PARP expression as
Andrew Yen, PhD
Received: April 30, 2008
Oncology (International Journal of Cancer Research and Treatment)
Vol. 76, No. 2, Year 2009 (Cover Date: February 2009)
Journal Editor: Markman M. (Houston, Tex.)
For additional information: http://www.karger.com/OCL
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.